These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
234 related articles for article (PubMed ID: 18046919)
1. Role of 5 alpha-reductase inhibitors in the management of prostate cancer. Hudak SJ; Hernandez J; Thompson IM Clin Interv Aging; 2006; 1(4):425-31. PubMed ID: 18046919 [TBL] [Abstract][Full Text] [Related]
2. Dutasteride and prostate cancer. Garattini S; Bertele' V N Engl J Med; 2010 Aug; 363(8):794; author reply 794-6. PubMed ID: 20842790 [No Abstract] [Full Text] [Related]
3. The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer. Tindall DJ; Rittmaster RS J Urol; 2008 Apr; 179(4):1235-42. PubMed ID: 18280514 [TBL] [Abstract][Full Text] [Related]
4. Preventive and therapeutic efficacy of finasteride and dutasteride in TRAMP mice. Opoku-Acheampong AB; Unis D; Henningson JN; Beck AP; Lindshield BL PLoS One; 2013; 8(10):e77738. PubMed ID: 24204943 [TBL] [Abstract][Full Text] [Related]
5. The utility of 5-alpha reductase inhibitors in the prevention and diagnosis of prostate cancer. Reed AB; Parekh DJ Curr Opin Urol; 2009 May; 19(3):238-42. PubMed ID: 19318950 [TBL] [Abstract][Full Text] [Related]
6. Overview of pivotal studies for prostate cancer risk reduction, past and present. Andriole GL Urology; 2009 May; 73(5 Suppl):S36-43. PubMed ID: 19375625 [TBL] [Abstract][Full Text] [Related]
7. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers. Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707 [TBL] [Abstract][Full Text] [Related]
12. A systematic review of the effects and mechanisms of preoperative 5α-reductase inhibitors on intraoperative haemorrhage during surgery for benign prostatic hyperplasia. Zong HT; Peng XX; Yang CC; Zhang Y Asian J Androl; 2011 Nov; 13(6):812-8. PubMed ID: 21892196 [TBL] [Abstract][Full Text] [Related]
15. The clinical applications of five-alpha reductase inhibitors. Loughlin KR Can J Urol; 2021 Apr; 28(2):10584-10588. PubMed ID: 33872554 [TBL] [Abstract][Full Text] [Related]
16. [Use of 5-alpha-reductase inhibitors in the prevention of prostate cancer]. Schulman C Ann Urol (Paris); 2004 Dec; 38 Suppl 2():S35-42. PubMed ID: 15651489 [TBL] [Abstract][Full Text] [Related]
17. Dutasteride: a review of its use in the management of prostate disorders. Keam SJ; Scott LJ Drugs; 2008; 68(4):463-85. PubMed ID: 18318566 [TBL] [Abstract][Full Text] [Related]
18. The effect of finasteride and dutasteride on the growth of WPE1-NA22 prostate cancer xenografts in nude mice. Opoku-Acheampong AB; Nelsen MK; Unis D; Lindshield BL PLoS One; 2012; 7(1):e29068. PubMed ID: 22242155 [TBL] [Abstract][Full Text] [Related]
19. Chemoprevention of prostate cancer. Vemana G; Hamilton RJ; Andriole GL; Freedland SJ Annu Rev Med; 2014; 65():111-23. PubMed ID: 24188663 [TBL] [Abstract][Full Text] [Related]